On Monday, April 25th, Fight Colorectal Cancer held a free patient webinar that tackled the somewhat complex but fascinating topic of personalized medicine.

Personalized medicine is what the cancer community calls treatments that are tailored to each patient’s genetic makeup. It is the future of cancer care and in some cases, it is already making a big difference in the ways patients are treated.

You can learn about these cutting edge treatments and about emerging findings in an archive of the webinar below.

Our thanks to Carolyn Grande, CRNP, AOCNP for leading the discussion. She a phenomenal educator on this topic and a member of our Medical Advisory Board. She graciously donated her time to bring this information to patients.

Medicine that is tailored to each patient’s genetic makeup is the future of cancer care. In some cases, it is already making a big difference in the ways patients are treated. Learn about these cutting edge treatments and about emerging findings that will be important for future diagnoses and treatments of colorectal cancer. Discussion led by Carolyn Grande, CRNP, AOCNP.

Fight Colorectal Cancer is giving you the opportunity to talk to researchers and medical professionals in April and May through online webinars designed to bring the science of treating colorectal cancer down to the personal.

The latest news from the petri dish
Wednesday, April 20, 2011
8 – 9 PM Eastern

Dr. Yaeger at work in her lab

Dr. Rona Yaeger will discuss the research she has been conducting over the past year with the grant she received as part of Fight Colorectal Cancer’s Lisa Fund research program.

Dr. Yaeger’s research focused on inhibiting the AKT pathway in colorectal cancer cells. She conducted basic research to determine how inhibitors to the pathway might affect cells of patients who have mutated KRAS and are resistant to EGFR inhibiting drugs. Dr. Yaeger has also been conducting a phase II clinical trial with an AKT inhibitor for patients with metastatic colorectal cancer who have normal (wild type) KRAS.

If you are interested in learning more about the future of cancer treatments, or if you’ve ever donated to the Fight Colorectal Cancer Lisa Fund, do not miss this webinar!

Read the rest of this entry »

Some of the most interesting data presented at ASCO was the data on MSI and 18qLOH in a European clinical trial.

Last year at ASCO, Dr. Daniel Sargent presented new data that patients with stage II disease with microsatellite instability do not only not benefit from 5-FU, but they may be harmed, and it was recommended to test for MSI in all stage II colon cancer patients and in the presence of MSI-high not to give 5-FU. For stage III colon cancer that was not the case.

This year, the PETACC-3 clinical trial was analyzed for MSI and did not show the same the same findings. It seems that chemotherapy does not harm these patients, and they may benefit. Read the rest of this entry »

A news release from last Wednesday stated that the clinical trial of NSABP C-08 was negative.

This was the clinical trial testing whether the addition of Avastin to FOLFOX would increase efficacy in reducing recurrence for patients with stage II and III colon cancer.  FOLFOX was given over 6 months compared to FOLFOX in combination with Avastin for 6 months, followed by additional 6 months of Avastin. There was a great hope that this anti-VEGF therapy would further decrease tumor recurrence. Read the rest of this entry »